Company GRI BIOPAR

Equities

GRI

US3622AW1069

Real-time Estimate Cboe BZX Other stock markets 11:36:38 2024-04-29 am EDT			5-day change	1st Jan Change
0.43 ^USD	0.00%		-18.55%	-93.53%

Apr. 16	GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments	MT
2023	Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Business Summary

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company's lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company's second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.

Number of employees: 2

Company contact information

Vallon Pharmaceuticals, Inc.

Two Logan Square 100 North 18th Street

19103, Philadelphia

http://www.vallon-pharma.com

Sector

This company's sector is not yet available